Team:Vanderbilt/Safety
From 2014.igem.org
(Difference between revisions)
Line 25: | Line 25: | ||
height: 60px;" | height: 60px;" | ||
colspan: 2; | colspan: 2; | ||
- | padding: | + | padding: 5px; |
} | } | ||
Line 32: | Line 32: | ||
</style> | </style> | ||
- | <center><img src="http://parts.igem.org/wiki/images/7/72/VU_iGem_Logo_%28Transparent.png" align="middle" width="500px"></center> | + | <center><img src="http://parts.igem.org/wiki/images/7/72/VU_iGem_Logo_%28Transparent.png" align="middle" width="500px" style="margin-left: 2px"></center> |
<!--main content --> | <!--main content --> | ||
<table width="70%" align="center" margin-bottom: "3cm"; style="border:4px solid black;" | <table width="70%" align="center" margin-bottom: "3cm"; style="border:4px solid black;" |
Revision as of 20:25, 8 February 2015

|
One area of extra concern is that the transformed E. coli strains used have antibiotic resistance genes against both ampicillin and kanamycin. If these organisms were to escape the lab environment, it is conceivable that these resistance genes could undergo lateral gene transfer. The spread of antibiotic resistance in this way is significant to considerations of public health. Aside from the number of laboratory precautions we had taken in terms of maintaining sterile technique and properly disposing of all possible biohazards, in the design of our project we noted that homologous recombination into yeast would greatly reduce the danger of resistance genes spreading to other organisms. |